Latest Conference Articles

Single-Dose of Dexamethasone Adequate With Palonosetron for Controlling CINV

Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based moderately emetogenic chemotherapy when compared with a longer duration of dexamethasone.

Netupitant-Palonosetron Combination Shows Continued Superiority Over Palonosetron for CINV

A treatment intended to control chemotherapy-induced nausea and vomiting that combines netupitant and palonosetron demonstrated superior activity in complete response rates over oral palonosetron monotherapy.

Aprepitant- and Metoclopramide-Based Regimens Demonstrate Similar Efficacy in Preventing Delayed Cisplatin-Induced Emesis

For the prevention of nausea and vomiting after the first day of cisplatin-based chemotherapy, both aprepitant and metoclopramide when used in combination with dexamethasone were found to be similarly effective.

Ramucirumab Benefit for US Patients With Gastric Cancer Mirrors Global Results

A geographic analysis of clinical trial results supporting the use of ramucirumab in advanced gastric cancer demonstrated that patients in the United States and other Western nations experienced similar survival gains and adverse events as did their counterparts in two other regions of the world.

Declan Walsh, MSc, FACP, FRCP, on the Under-Diagnosis of Malnutrition

Declan Walsh, MSc, FACP, FRCP, director, 2014 MASCC/ISOO International Symposium, discusses the under-diagnosis of malnutrition in palliative medicine.

Regorafenib Offers Effective Option for Asian Patients With mCRC

Treatment with regorafenib significantly improved OS and PFS in an Asian population of patients with previously treated mCRC.

MM-398 Improves OS, PFS in Phase III Pancreatic Cancer Study

Second-line treatment with MM-398 plus 5-FU and leucovorin extended OS, PFS, and ORR compared with 5-FU and leucovorin alone for patients with metastatic pancreatic cancer.

Alex Molasiotis, RN, PhD, on the Management on Breathlessness

Alex Molasiotis, RN, PhD, discusses the results of a pilot feasibility study looking at inspiratory muscle training for the management of breathlessness in patients with lung cancer.

Dr. Roila on Aprepitant for the Prevention of Cisplatin-Induced Delayed Emesis

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis.

Dr. Peeters on the Frequency of S492R Mutations Following EGFR Inhibition in mCRC

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.

Dr. Tabernero on Sequencing Angiogenesis Inhibitors in mCRC

Josep Tabernero, MD, PhD, head, Medical Oncology Department, Vall d'Hebron University Hospital, director, Vall d'Hebron Institute of Oncology, discusses his opinions on which patients with metastatic colorectal cancer should receive aflibercept following bevacizumab.

Dr. Keefe Discusses Links Between Toxicities

Dorothy M. K. Keefe, MD, FRACP, past president, MASCC, director, SA Cancer Service, professor of cancer medicine, University of Adelaide, discusses links between toxicities associated with anticancer drugs.

Dr. Raftopoulos on Pulmonary Toxicity With EGFR TKIs

Haralambos Raftopoulos, MD, associate professor, Hofstra North Shore-LIJ School of Medicine, discusses pulmonary toxicity with EGFR tyrosine kinase inhibitors (TKIs).

Ruxolitinib Combo Improves Outcomes in Metastatic Pancreatic Cancer

Adding ruxolitinib to capecitabine as a second-line treatment for patients with metastatic pancreatic cancer significantly improved survival for a subgroup with a high degree of local and systemic inflammation compared with capecitabine plus placebo.

Adding Cetuximab to Chemoradiation in Non-operable Esophageal Cancer Does Not Improve Survival

Adding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus

Prognostic Scale Developed for Overall Survival in Locally Advanced Pancreatic Cancer

Four independent prognostic factors for improved overall survival in patients with locally advanced pancreatic cancer emerged from an analysis of the LAP 07 phase III trial.

Ã…ge Schultz, DVM, PhD, Discusses the Cost of Supportive Care Medicine

Ã…ge Schultz, DVM, PhD, executive director, Multinational Association of Supportive Care in Cancer (MASCC), discusses pain management and the cost of supportive care medicine.

Dr. O'Reilly on Nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX in Pancreatic Cancer

Eileen M. O'Reilly, MD, associate director, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discusses using nab-paclitaxel plus gemcitabine versus FOLFIRINOX as treatment for patients with untreated metastatic pancreatic cancer.

Dr. Tempero Discusses Hereditary Pancreatic Cancer

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the two main types of hereditary pancreatic cancer.

Continuing Afatinib Beyond Progression Improves PFS in Metastatic NSCLC

Continuing EGFR inhibition beyond progression with afatinib plus paclitaxel significantly improved PFS and ORR compared with chemotherapy alone in patients with heavily pretreated metastatic NSCLC.

Pembrolizumab Induces Robust Responses in PD-L1-positive NSCLC

The anti-PD-1 humanized antibody pembrolizumab has robust antitumor activity as a first-line treatment for patients with advanced PD-L1-positive NSCLC.

Necitumumab Delivers Rare Survival Benefit in Squamous NSCLC

Adding necitumumab to standard of care with gemcitabine-cisplatin significantly improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV non–small-cell lung cancer of squamous histology.

Dr. Younes on R-CHOP in Combination with Ibrutinib in DLBCL

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses a phase III study of ibrutinib in combination R-CHOP in patients with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma.

Panobinostat Combination Improves PFS in Multiple Myeloma

Combining panobinostat (LBH589) with bortezomib and dexamethasone delayed disease progression by 3.9 months over bortezomib and dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma.

Anti-CD38 Antibody Generates Excitement in Multiple Myeloma

The CD38-specific monoclonal antibody SAR650984 demonstrated encouraging efficacy as a monotherapy and in combination with dexamethasone and lenalidomide without reaching a maximum tolerated dose in patients with heavily pretreated multiple myeloma.

Follow-up of Concurrent Immunotherapies Shows Unprecedented Survival Rate in Melanoma

Long-term follow-up results demonstrated nearly doubled median OS with the combination of ipilimumab and nivolumab compared with either agent alone.

Dr. Spigel Discusses MPDL3280A Development in Lung Cancer

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses current trials involving MPDL3280A in lung cancer.

'Smart' Alkylator TH-302 Shows Clinical Benefit in Early Multiple Myeloma Trial

The addition of the investigational hypoxia-targeted drug TH-302 to dexamethasone has demonstrated beneficial activity and a manageable adverse event profile in the treatment of patients with relapsed/refractory multiple myeloma.

Novel Rituximab Combinations Highly Effective in CLL

The novel agents idelalisib and ABT-199 in combination with rituximab have demonstrated impressive activity with manageable toxicity for patients with relapsed or refractory chronic lymphocytic leukemia.

Practice-Changing Data Revealed for Premenopausal HR+ Breast Cancer

A joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptor–positive (HR+) breast cancer demonstrated that adjuvant use of the aromatase inhibitor (AI), exemestane, reduced relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS).